Eastern Cooperative Oncology Group (ECOG) performance status of ? 2 for Part 1 and ? 1 for Part 2. Adequate organ function.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 within 2 weeks prior to screening
Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0-1\r\n* NOTE: Participants with impaired decision-making capacity (IDMC) should not be allowed to participate in this study due to its complexity
Eastern Cooperative Oncology Group (ECOG) performance status of =< 1 within 90 days prior to step 1 registration
Eastern Cooperative Oncology Group (ECOG) performance status 0-1 60 days prior to registration
Eastern Cooperative Oncology Group (ECOG) status 0-2 within 1 month prior to registration
Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 within 7 days of enrollment
Eastern Cooperative Oncology Group (ECOG) performance status of zero to two unless decline is due to bony disease
ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 14 days prior to registration
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 10 days prior to the start of study treatment.
Patients must be ambulatory with good performance status (Eastern Cooperative Oncology Group [ECOG] 0 or 1)
INCLUSION CRITERIA FOR SECOND-LINE THERAPY: Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Eastern Cooperative Oncology Group (ECOG) performance status must be ?2 (Appendix A).
SAFETY RUN-IN: Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Eastern cooperative oncology group (ECOG) performed status of 0, 1 or 2; 0 or 1 (cohort E only)
Eastern Collaborative Oncology Group (ECOG) Performance Status of 0-1 (Appendix 1).
Eastern Cooperative Oncology Group (ECOG) performance status =< 3 or Lansky performance status of >= 30
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 10 days of randomization.
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 10 days of study start
ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Eastern Cooperative Oncology Group (ECOG) performance status =< 2
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 within 28 days prior to study registration.
Eastern Cooperative Oncology Group (ECOG) performance status 0 – 2 (asymptomatic to symptomatic but capable of self-care) within 45 days prior to randomization
Eastern Cooperative Oncology Group performance status of less than or equal to (</=) 2
Eastern Cooperative Oncology Group (ECOG) performance status of ? 1 and adequate organ function
Eastern Cooperate Oncology Group (ECOG) performance status =< 2
Eastern Cooperative Oncology Group (ECOG) performance status 0-1 as documented within 3 months prior to study entry
Eastern Collaborative Oncology Group (ECOG) performance status of 0 or 1 at screening
Patients must demonstrate an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Eastern Cooperative Oncology Group (ECOG) performance status of ? 1, measured within 72 hours before the start of treatment.
Eastern Collaborative Oncology Group (ECOG) Performance Status of ?2
Eastern Cooperative Oncology Group performance status less than or equal to 2
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 with no clinical deterioration over the previous 2 weeks and likely able to complete at least 9 weeks of treatment.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Appendix A)
European Cooperative Oncology Group (ECOG) performance status 0 or 1.
Eastern Cooperative Oncology Group (ECOG) performance status 0-1 within 30 days prior to registration
Eastern Cooperative Oncology Group (ECOG) performance status =< 2; performance status of 3 will be accepted if impairment is caused by DLBCL complications and improvement is expected once therapy is initiated
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Phase I), =< 1 (Phase II)
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 within 14 days prior to being registered for protocol therapy
Eastern Cooperative Oncology Group (ECOG) performance status 0-2 assessed within 90 days of enrollment
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 7 days prior to the date of allocation/randomization
Eastern Cooperative Oncology Group (ECOG) performance status of 2 or better
Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1 at enrollment and within 7 days of initiating lymphodepleting chemotherapy.
Eastern Cooperative Oncology Group (ECOG) performance status of =< 1 within 14 days prior to registration. Cisplatin-ineligible chemotherapy-naive subjects may have an ECOG performance status of =< 2.
Eastern Cooperative Oncology Group performance status 0-1 at time of informed consent
For cohorts 1-3, clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1
COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Patients must be medically fit to undergo surgery as determined by the treating medical and surgical oncology team and have Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
Eastern Cooperative Oncology Group (ECOG, Appendix F) Performance Status of ? 1
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (within 28 days prior to enrollment)
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 within 14 days prior to being registered for protocol therapy
Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, with no deterioration over the previous 2 weeks.
Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (see Appendix 14.3)
Eastern Cooperative Oncology Group (ECOG) status of 0, 1, or 2 within 28 days prior to registration
Eastern Cooperative Oncology Group (ECOG) performance status of 0-3, however grade 4 patients may be enrolled at the discretion of the treating radiation oncologist
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (must be done within 7 days prior to study drug administration)
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 for patients treated in the expansion phase; ECOG performance status (PS) =< 1 is required for participants in the dose-finding portion of the study
have an Eastern Cooperative Oncology Group (ECOG) performance status of ?1 (Appendix II);
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; able to understand and sign the Informed Consent document
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 within 28 days prior to randomization
Eastern Co-operative Oncology Group (ECOG) performance status < or = 2.
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at initial screening and at baseline.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 28 days prior to registration for protocol therapy
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2; (performance status of 3 will be allowed if poor performance status is thought to be directly secondary to ALL)
Eastern Cooperative Oncology Group (ECOG) performance status of =< 2 within 28 days prior to registration
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; patients with an ECOG performance status of 2 will be allowed at the discretion of the treating investigator in agreement with the sponsor-investigator
Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 for Monotherapy and 0 to 1 for Combination.
Eastern Cooperative Oncology Group (ECOG) performance status of =< 2 or greater, based on treating physician’s discretion
Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2 (Appendix D).
European Cooperative Oncology Group (ECOG) performance status 0 or 1
Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 at time of informed consent
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 or expected survival duration of > 2 months
Eastern Cooperative Oncology Group (ECOG) performance status of =< 2 and fit for induction therapy in the opinion of the treating physician
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 or better
History/physical examination, including breast exam and documentation of weight and Eastern Cooperative Oncology Group (ECOG) performance status
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, 2, or 3, if the performance status of 3 is due to skin disease involvement
Eastern Cooperative Oncology Group (ECOG) performance status scores of 0, 1, or 2
Eastern Cooperative Oncology Group (ECOG) performance status of =< 1 within 14 days prior to being registered for protocol therapy
The subject must have a performance status of 0-1 as determined by criteria set forward by the Eastern Cooperative Oncology Group
Eastern Co-operative Oncology Group (ECOG) performance status of ? 2.
Patients must have a performance status of 0 to 2 according to the Eastern Cooperative Oncology Group (ECOG) criteria
Current Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 through screening to first treatment on study
Eastern Cooperative Oncology Group (ECOG) performance status of 2 or better
CAPMATINIB INCLUSION CRITERIA: Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Eastern Cooperative Oncology Group (ECOG) performance status and/or other performance status 0, 1, or 2; performance status of 3 permissible if related to disease
Eastern Cooperative Oncology Group (ECOG) performance status 0,1 (Appendix D)
Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 - 1 within 30 days of signing informed consent
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nEastern Cooperative Oncology Group (ECOG) performance status =< 2
Eastern Cooperative Oncology Group (ECOG) performance status of zero, one, or two
Eastern Cooperative Oncology Group (ECOG) performance status 0–2 (3 if it is directly disease related and is expected to get better if the acute lymphoblastic leukemia/lymphoma [ALL] is under control)
Eastern Cooperative Oncology Group (ECOG) performance status must be level 0 or 1 within 60 days prior to registration
Adequate performance status (Eastern Cooperative Oncology Group [ECOG] < 3) and research participant does not require mechanical ventilation
Eastern Clinical Oncology Group performance status 0 or 1
Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0-2 within 30 days of signing informed consent (Turnstile I)
Eastern Clinical Oncology Group performance status 0 or 1
Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging Network (ACRIN) performance status between 0-2
Relapsed/refractory MCL: Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less
Newly diagnosed MCL: Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less
Patient eligible for standard induction chemotherapy based on Eastern Cooperative Oncology Group (ECOG) performance status (PS) and vital organ function at the discretion of the treating physician
Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0-2 within 30 days of signing informed consent (Turnstile I)
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 within 7 days prior to registration
Eastern Cooperative Oncology Group (ECOG) performance status 2 or better
Patients must be ambulatory with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Eastern Cooperative Oncology Group (ECOG) status 0-1 documented within 90 days of registration
Participants will not be excluded based on performance status; for patients with Eastern Cooperative Oncology Group (ECOG) performance status >= to 3 the dosing schedule will be discussed with study chairman
Patients > 70 may be considered if performance status > 80% or Eastern Cooperative Oncology Group (ECOG) =< 1 and comorbidity score < 3; these patients must be discussed with the principal investigator (PI), Rachel Salit prior to enrollment
Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0-2 (Turnstile I)
Easter Cooperative Oncology Group (ECOG) Performance Status ? 1
Eastern Cooperative Oncology Group (ECOG) performance status grade less than or equal to (<=) 2
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 within 14 days prior to registration for protocol therapy
Eastern Cooperative Oncology Group (ECOG) performance status and/or other performance status 0, 1, or 2 at time of enrollment.
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 within 28 days prior to registration
ORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Eastern Cooperative Oncology Group (ECOG) performance status < 2
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days prior to the first dose of study treatment but before randomization.
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, and estimated survival of at least 3 months
Eastern Cooperative Oncology Group (ECOG) performance status of =< 3 and fit for induction therapy in the opinion of the treating physician
REGISTRATION TO TREATMENT (STEP 1): Patients have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2 and expected survival > 3 months from study enrollment
Eastern Cooperative Oncology Group (ECOG) performance status being 0-1 within 1 week of planned start of therapy
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 within 28 days prior to registration
FOR TISSUE COLLECTION TO ESTABLISH PDX (PART 1): Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 28 days prior to registration for protocol therapy
The subject must have a performance status of 0-2 as determined by criteria set forward by the Eastern Cooperative Oncology Group
DOSE ESCALATION COHORT: Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 30 days prior to registration.
Eastern Cooperative Oncology Group (ECOG) performance status 0-2 at time of study entry
PSTAT3 SCREENING: Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 14 days before registration for protocol therapy
Performance status of 2 or better as per Eastern Cooperative Oncology Group (ECOG) criteria
Easter Cooperative Oncology Group (ECOG) performance status 0-2
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at initial enrollment, as assessed by clinician or investigator
Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 - 1; ECOG performance status of 0-1 will be inferred if the patient’s level of energy is >= 50% of baseline
Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 - 1; ECOG performance status of 0-1 will be inferred if the patient's level of energy is >= 50% of baseline
Performance Status: Eastern Cooperative Oncology Group (ECOG) 0-1 unless mobility is limited from chronic physical handicap
Eastern Cooperation Oncology Group (ECOG) performance status 0-2
Patients must have Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging Network (ACRIN) performance status of 0-2
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 10 days prior to study start
Eastern Cooperative Oncology Group (ECOG) performance less than or equal to 2
Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 at the time of informed consent
The participant has an Eastern Cooperative Oncology Group performance status of 0 or
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; patients with ECOG performance status of 3 will be eligible if the lower performance status is deemed by the investigator to be due entirely to accelerated or blastic phase MPN and not due to another comorbidity
Patients who have received one prior regimen must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2; patients who have received two or three prior regimens must have an ECOG performance status of 0 or 1
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 10 days prior to study start
Performance status of 2 or better as per Eastern Cooperative Oncology Group (ECOG) criteria
AMKL PATIENTS: Patients must have an Eastern Cooperative Oncology Group (ECOG) status 0-2
Eastern Cooperative Oncology Group (ECOG) Performance status less than or equal to (</=) 2 (for dose-escalation part) and 0 or 1 (for dose-expansion part)
The subject has an Eastern Cooperative Oncology Group performance (ECOG) status ? 1 at Screening and Day 1
Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. (Appendix F);
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 within 14 days prior to randomization.
Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, 2, or 3 within 28 days prior to registration
Eastern Cooperative Oncology Group performance status superior to 2.
ECOG (Eastern Cooperative Oncology Group) Performance Status of 0-2 within 28 days prior to registration. ECOG Performance Status of 3 will only be allowed if judged by the treating investigator as attributable exclusively to bone pain.
Eastern Cooperative Oncology Group performance status of 0 to1. For LM patients, 0 to 2 is acceptable.
Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0-2 within 30 days of signing informed consent
Has an Eastern Cooperative Oncology Group (ECOG) performance status of ? 3 (? 2 during dose escalation)
Eastern Cooperative Oncology Group (ECOG) performance status of 0 – 1 within 14 days prior to study registration
Eastern Co-Operative Group (ECOG) performance status = 0 - 2
Easter Cooperative Oncology Group (ECOG) performance status 0 or 1
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 as long as patients are eligible to receive chemotherapy along with concurrent radiotherapy
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Patients with performance status 2 are only eligible if the decline in performance status is due to metastatic prostate cancer.
Patients who have received one prior regimen must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Eastern Cooperative Oncology Group (ECOG) performance status of 1 or better
Eastern Cooperative Oncology Group performance status 0-1 at time of informed consent
Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status: ECOG of 0 or 1 including patients who are not surgical candidates due to comorbid conditions
Must have a radiographically or clinically evaluable solid tumor Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 or better
Patients must have a performance status of 0 to 1 according to the Eastern Cooperative Oncology Group (ECOG) criteria
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (2 is allowed only if due to bone pain)
Men and women ? 18 years of age with an Eastern Cooperative Oncology Group (ECOG) performance status ? 1
Subjects must have Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2; if ECOG 2, they must also have a Charlson comorbidity index of =< 5
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 with no deterioration over the previous 2 weeks.
Eastern Cooperative Oncology Group performance status less than or equal to 2
PRE-REGISTRATION INCLUSION CRITERIA: Eastern Cooperative Oncology Group (ECOG) performance status =< 1
STEP 2 ENROLLMENT AND RANDOMIZATION: the patient’s Eastern Cooperative Oncology Group (ECOG) performance status is =< 2 at study entry
Patients must have a performance status of 0 to 2 according to the Eastern Cooperative Oncology Group (ECOG) criteria
Eastern Cooperative Oncology Group (ECOG) performance status =< 1 for ages >= 16 or Lansky play >= 80% for ages =< 15
World Health Organisation (WHO) or Eastern Cooperative Oncology Group (ECOG) Performance status 0-2.
Easter Cooperative Oncology Group (ECOG) Performance Status of 0-2
The Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status of 2-3.or patients with chronic lymphocytic leukemia requiring treatment age >65 years at the time of signing informed consent and ECOG/WHO performance status of 0-1 and a CIRS or Charlson co-morbidity score of 2 or higher.
Eastern Cooperative Oncology Group (ECOG) performance status of =< 2 or greater, based on treating physician's discretion
Have a performance status less than or equal to 1 for Dose Escalation (Part A) and less than or equal to 2 for Dose Confirmation (Parts B, C, D, E, F and G) on the Eastern Cooperative Oncology Group (ECOG) scale
Clinical performance status of Eastern Cooperative Oncology Group (ECOG) less than or equal to 1
Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed within 10 days of treatment initiation.
Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (see Appendix 14.3)
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 within 14 days prior to registration
Easter Cooperative Oncology Group (ECOG) performance status of 0,1,or 2
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 10 days prior to registration for protocol therapy
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at the time of screening and enrollment
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 within 28 days prior to registration.
Subject has Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2 at screening.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 14 days before enrollment.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 14 days before enrollment.
Eastern Cooperative Oncology Growth (ECOG) performance status =< 2
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 14 days prior to the initiation of study treatment
Eastern Cooperative Oncology Group (ECOG) performance status measure will be used; (ECOG performance status less than or equal to 3)
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 within 14 days of study entry
Eastern Cooperative Oncology Group performance status less than or equal to 2.
Patients must have a Eastern Cooperative Oncology Group status of </=2.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 in Parts 1 and 2 dose escalation and titration, and 0, 1, 2 in Part 3 dose expansion
Eastern Cooperative Oncology Group (ECOG) performance status of =< 1 within 14 days prior to dose 1 of mirvetuximab soravtansine
Eastern Cooperative Oncology Group (ECOG) performance status of equal or less than 3 at study entry
Performance status 0-1 (Eastern Cooperative Oncology Group classification);
European Cooperative Oncology Group (ECOG) performance status of ? 2
Patient has received a platinum containing regimen. Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Radiographically-documented measureable disease.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (Appendix C).
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 within 14 days prior to first dose of study drug.
Willingness to provide consent for biopsies positive or BRAF WT measurable disease, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate organ and marrow function
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 within 14 days prior to first dose of study treatment.
Eastern Co-operative Oncology Group (ECOG) performance status of 0-2
Eastern CooperativeOncology Group (ECOG) performance status of 0 or 1
Eastern Cooperative Oncology Group status of 2 or lower
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 in Part 1 and Part 2, participants enrolled in the extension/tail portion, Part 3 and Part 4 must have an ECOG performance status of 0 or 1
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 for run-in phase; ECOG =< 1 for randomized phase
History/physical examination, including weight and assessment of Eastern Cooperative Oncology Group (ECOG) performance status, within 1 month of registration
Eastern Cooperative Oncology Group (ECOG) performance status of =< 2; NOTE: For the phase I part of the study, patients with ECOG performance status 2 will be excluded
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 within 14 days of study entry
Eastern Cooperative Oncology Group Performance Status of 0 or 1 for Parts A and B. Subjects with Eastern Cooperative Oncology Group Performance Status of 2 or less may be entered into Part C with approval of medical monitor.
Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 - 1 within 30 days of signing informed consent
Eastern Cooperative Oncology Group (ECOG) performance status ? 1. Patients with stable ECOG scores of 2 may be allowed with medical monitor approval.
Eastern Cooperative Oncology Group (ECOG) Performance status assessed between 0 and 2; performance status of 3 will be accepted if impairment is caused by DLBCL complications and improvement is expected once therapy is initiated
PATIENT: Eastern Cooperative Oncology Group (ECOG) performance status from 0 (asymptomatic) to 3 (symptomatic and in bed > 50% of the day)
Eastern Cooperative Oncology Group (ECOG) performance status from 0 (asymptomatic) to 2 (symptomatic and in bed < 50% of day)
Patient is spending more than 50% of time out of bed on a daily basis, as measured by an Eastern Cooperative Oncology Group (ECOG) performance status rating of level 0, 1, or 2
Eastern Cooperative Oncology Group (ECOG) performance status 0-1 during dose finding, 0-2 during MTD expansion
Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed within 10 days prior to receiving the first dose of study therapy
Eastern Cooperative Oncology Group (ECOG) performance status from 0 (asymptomatic) to 2 (symptomatic and in bed < 50% of the day)
Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 at time of initial screening
Patients are eligible regardless of Eastern Cooperative Oncology Group (ECOG) performance status
There will be no discrimination based on gender, race, creed, or ethnic background; Eastern Cooperative Oncology Group (ECOG)/Karnofsky performance scale (KPS) will not be employed
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 28 days prior to initiation of treatment
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (0=participant has either normal activity, 1= participant has some symptoms but is nearly full ambulatory)
Eastern Cooperative Oncology Group (ECOG) rating of >= 3 or Karnofsky performance status (KPS) < 60 as rated by the oncology provider
Eastern Cooperative Oncology Group (ECOG) performance status from 0 (asymptomatic) to 2 (symptomatic and in bed < 50% of the day)
SCREENING PHASE: Eastern Cooperative Oncology Group performance status 0-2
INTERVENTION PHASE: Eastern Cooperative Oncology Group performance status 0-2
Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (within 90 days of enrollment)
Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (at the time the subject signs their first informed consent form);
Easter Cooperative Oncology Group (ECOG) performance status 0 or 1
Eastern Cooperative Oncology Group (ECOG) ranging from 0 (asymptomatic) to 2 (symptomatic and in bed > 50% of the day)
Eastern Cooperative Oncology Group performance status of 0 or 1 as assessed within 21 days prior to randomization.
Patients with an Eastern Cooperative Oncology performance status of 0 or 1
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at Screening or by the day chemotherapy is initiated
Eastern Cooperative Oncology Group (ECOG) performance status 2 or better
Eastern Cooperative Oncology Group (COG) performance status of 0-2
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (fully active or restricted only in physically strenuous activity)
Eastern Cooperative Oncology Group (ECOG) performance status >2 (See Appendix G)
Eastern Cooperative Oncology Group (ECOG) performance status of =< 2 within 28 days prior to registration
Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1 within 28 days of registration
The Eastern Cooperative Oncology Group (ECOG) performance status of 1 or better
The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 or, based on judgment of the treating medical oncologist, can tolerate imaging and at least 6 months of ET
Eastern Cooperative Oncology Group (ECOG) performance status of =< 1 within 14 days prior to being registered for protocol
Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance status will not be employed, but patients will need to be sufficiently healthy to tolerate all study procedures
AIM 3: Participants must be Eastern Cooperative Oncology Group (ECOG) status 0-3
Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, with no deterioration over the previous 2 weeks
Easter Cooperative Oncology Group (ECOG) performance status 0 or 1
Non-metastatic GI cancers are eligible only if the Eastern Cooperative Oncology Group (ECOG) performance status is 2, 3, or 4 at the time of consent (although patients with locally advanced [stage III] and inoperable pancreatic cancers are eligible regardless of their performance status)
Women and men ?18 years of age with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, as assessed within 10 days prior to the start of study drug.